Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk - Concepedia

Concepedia

Publication | Closed Access

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

79

Citations

20

References

2022

Year

Ruth M. de Tute, Charlotte Pawlyn, David A. Cairns, Faith E. Davies, Tom Menzies, Andy C. Rawstron, John R. Jones, Anna Hockaday, Rowena Henderson, Gordon Cook,

Journal of Clinical Oncology

Abstract

In patients with multiple myeloma, MRD status at both ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS.

References

	Year	Citations

Page 1